The US Food and Drug Administration (FDA) has granted Ridgeback Biotherapeutics LP, a biotechnology company, Breakthrough Therapy designation for its mAb114, an experimental Ebola treatment, it was reported on Friday.
Breakthrough Therapy designation is intended to accelerate the development and review of drugs for serious or life-threatening conditions.
The criteria for Breakthrough Therapy designation needs preliminary clinical evidence that indicates that the drug is likely to have substantial improvement on around one clinically significant endpoint over available therapy. Breakthrough Therapy designation for mAb114 was based on interim data from the Pamoja Tulinde Maisha (PALM [together save lives]) study, co-sponsored and funded by the INRB (Institut National de Recherche Biomédicale) and the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health and carried out by an international research consortium coordinated by the World Health Organization (WHO).
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT